Biphenyl

Biphenyl

SCHEMBL17044634

Cc1ccc(S(=O)(=O)OCCCCCCCCCCCCOCCCCCCCCCCCCOS(=O)(=O)c2ccc(C)cc2)cc1.c1ccc(-c2ccccc2)cc1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP24A1 Q07973 1/20 0.44
ALDH1A1 P00352 2/20 0.42
VDR P11473 1/20 0.40
PARL Q9H300 1/20 0.40
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
STAT3 P40763 1/20 0.39
CA12 O43570 3/20 0.38
CA9 Q16790 3/20 0.38
LMNA P02545 2/20 0.38
CA2 P00918 1/20 0.38
MCOLN3 Q8TDD5 1/20 0.38
HPGD P15428 1/20 0.38
CYP3A4 P08684 2/20 0.38
CA1 P00915 1/20 0.38
CYP2C19 P33261 1/20 0.38
GAA P10253 1/20 0.38
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2550352 0.89 ALDH1A1 (0.50) CYP24A1ALDH1A1VDRSTAT3CA12
SCHEMBL18428703 0.86 ALDH1A1 (0.47) CYP24A1ALDH1A1SMN1; SMN2CA12CA9
SCHEMBL9144282 0.86 FKBP1A (0.44) CYP24A1
SCHEMBL12737574 0.86 ALDH1A1 (0.50) CYP24A1ALDH1A1VDRSMN1; SMN2STAT3
SCHEMBL21618180 0.86 ALDH1A1 (0.50) CYP24A1ALDH1A1VDRSMN1; SMN2STAT3
SCHEMBL25206305 0.86 ALDH1A1 (0.48) CYP24A1ALDH1A1SMN1; SMN2CA12CA9
SCHEMBL9872166 0.86 ALDH1A1 (0.48) CYP24A1ALDH1A1SMN1; SMN2CA12CA9
SCHEMBL2241875 0.86 ALDH1A1 (0.48) CYP24A1ALDH1A1SMN1; SMN2CA12CA9
SCHEMBL29172709 0.86 ALDH1A1 (0.48) CYP24A1ALDH1A1SMN1; SMN2CA12CA9
SCHEMBL26979071 0.86 ALDH1A1 (0.48) CYP24A1ALDH1A1SMN1; SMN2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9719018-B2 Monomer, liquid crystal composition, liquid crystal display device, and production method for liquid crystal display device SHARP KABUSHIKI KAISHA (JP) 2017-08-01 US disclosed
US-20150247090-A1 MONOMER, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY DEVICE, AND PRODUCTION METHOD FOR LIQUID CRYSTAL DISPLAY DEVICE SHARP KABUSHIKI KAISHA (JP) 2015-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150247090-A1 MONOMER, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DISPLAY DEVICE, AND PRODUCTION METHOD FOR LIQUID CRYSTAL DISPLAY DEVICE NLRP1, PYCARD, NLRP3 CYP24A1 1831/4885ALDH1A1 3294/4885VDR 1350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.